An increase in the percent of PBMNCs expressing CD34+ in HHT patients was observed, although there were no differences seen in the fraction of PBMNCs staining positive for CD133 or CD34/VEGFR2. This evidence concerns the gene CD34 and hereditary hemorrhagic telangiectasia.